ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (H-REPLACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03363035
Recruitment Status : Recruiting
First Posted : December 5, 2017
Last Update Posted : December 4, 2018
Sponsor:
Information provided by (Responsible Party):
Shenghua Zhou, Second Xiangya Hospital of Central South University

November 29, 2017
December 5, 2017
December 4, 2018
January 15, 2018
December 31, 2019   (Final data collection date for primary outcome measure)
  • Primary Safety Outcome: The percentage of patients with minor, clinically relevant non-major (CRNM) and major bleeding [International Society on Thrombosis and Haemostasis (ISTH) definition of bleeding] [ Time Frame: From the time of randomization (Day 1) up to completion of the follow up phase (Month 6) ]
    The percentage of patients with the first occurrence of bleeding event according to ISTH definition. The statistical analysis was based on the occurrence of the bleeding event from randomization to Month 6.
  • Primary Efficacy Outcome: The percentage of patients with the composite endpoint of cardiac death, myocardial infarction, re-revascularization or stroke. [ Time Frame: From the time of randomization (Day 1) up to completion of the follow up phase (Month 6). ]
    The percentage of patients with the first occurrence of the composite of death, myocardial infarction, re-revascularization or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event up to Month 6.
Same as current
Complete list of historical versions of study NCT03363035 on ClinicalTrials.gov Archive Site
  • The percentage of patients with the cardiac-related rehospitalization. [ Time Frame: From the time of randomization (Day 1) up to completion of the follow up phase (Month 6). ]
    The percentage of patients with the cardiac-related rehospitalization. The statistical analysis was based on the time from randomization to the first occurrence of the event up to Month 6.
  • The percentage of patients with the all-cause death. [ Time Frame: From the time of randomization (Day 1) up to completion of the follow up phase (Month 6). ]
    The percentage of patients with the all-cause death. The statistical analysis was based on the time from randomization to the first occurrence of the event up to Month 6.
Same as current
Not Provided
Not Provided
 
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial
H-REPLACE trial is a prospective, randomized, open-label, active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI, unstable angina). All eligible participants receiving background treatment of aspirin plus clopidogrel or ticagrelor will be randomly assigned to either oral rivaroxaban 2.5 mg twice daily or rivaroxaban 5 mg twice daily or subcutaneous (SC) enoxaparin 1mg/kg twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

Acute coronary syndrome (ACS) is a serious and life threatening condition. Anticoagulation during the acute phase of ACS is effective in reducing ischaemic events. The combination regimen of anticoagulation with dual antiplatelet therapy (DAPT) strategy is more effective than either treatment alone. The most widely used parenteral anticoagulation agent in ACS patients is enoxaparin (1 mg/kg administered subcutaneously twice daily).

Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an attractive alternative drug to enoxaparin. In fact, rivaroxaban was consistently shown to be non-inferior to enoxaparin therapy aimed to reduce the event of recurrent venous thromboembolism. Moreover, the bleeding risk of low dose of rivaroxaban is low and acceptable (1.0-2.5%) during the acute phase of ACS as shown by ATLAS ACS-TIMI 46 Trial, and the bleeding risk of enoxaparin during the acute phase of ACS was 4.3% as shown in a meta-analysis.

We thus hypothesized that the safety and efficacy of rivaroxaban during the acute phase of ACS is non-inferior to enoxaparin and designed this prospective, randomized, open-label, active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI or unstable angina). All eligible participants receiving background treatment of aspirin plus clopidogrel or ticagrelor will be randomly assigned to either receive oral rivaroxaban 2.5 mg twice daily or oral rivaroxaban 5 mg twice daily or enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Myocardial Ischemia
  • Unstable Angina
  • Drug: Rivaroxaban 2.5 mg
    One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
    Other Name: Xarelto
  • Drug: Rivaroxaban 5 mg
    One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
    Other Name: Xarelto
  • Drug: Enoxaparin
    Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
    Other Name: LWMH
  • Experimental: Rivaroxaban 2.5 mg
    One 2.5 mg rivaroxaban tablet twice daily
    Intervention: Drug: Rivaroxaban 2.5 mg
  • Experimental: Rivaroxaban 5 mg
    One 5 mg rivaroxaban tablet twice daily
    Intervention: Drug: Rivaroxaban 5 mg
  • Active Comparator: enoxaparin
    Enoxaparin 1mg/kg twice daily SC twice daily
    Intervention: Drug: Enoxaparin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
3390
Same as current
May 31, 2020
December 31, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female aged ≥ 18 years
  • Diagnosed with ACS (STEMI, NSTEMI, unstable angina)
  • With an indication for short-term combination use of DAPT and enoxaparin.

Exclusion Criteria:

  • Already received thrombolytic therapy or revascularization or needing revascularization therapy in 12 hours.
  • With platelet glycoprotein IIb/IIIa receptor antagonist therapy.
  • With increased bleeding risk, such as but not limited to, active internal bleeding, clinically significant bleeding, bleeding at a non-compressible site, or bleeding diathesis within 30 days of randomization; platelet count less than 90,000/μL at screening; intracranial hemorrhage; major surgery, biopsy of a parenchymal organ, or serious trauma within 30 days before randomization; clinically significant gastrointestinal bleeding within 12 months before randomization; an international normalized ratio known to be>1.5 at the time of screening; abciximab bolus or infusion within the preceding 8 hours, or an eptifibatide or tirofiban bolus or infusion within the past 2 hours preceding randomization; or any other condition known to increase the risk of bleeding.
  • Severe concomitant condition or disease, such as cardiogenic shock at the time of randomization, ventricular arrhythmia refractory to treatment at the time of randomization, calculated creatinine clearance b 30 mL/min at screening, known significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis), or liver function test abnormalities (confirmed with repeat testing) which would require study drug discontinuation, i.e., aminoleucine transferase (ALT) >5 × the upper limit of the normal range (ULN) or ALT >3 × ULN plus total bilirubin >2 × ULN, prior ischemic stroke or transient ischemia attack, anemia (i.e., hemoglobin < 10 g/ dL= at screening, known clinical history of human immunodeficiency virus infection at screening, substance abuse (drug or alcohol) problem within the previous 6 months or any severe condition such as cancer that would limit life expectancy to less than 6 months.
  • With an indication for long-term oral anticoagulation therapy such as atrial fibrillation, venous thromboembolism, or prior placement of a mechanical heart valve.
  • With other contraindications for use of rivaroxaban and enoxaparin.
  • Enrolled in another clinical study.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Shenghua Zhou, Ph.D. +86 0731-85292013 zhoushenghua@csu.edu.cn
China
 
 
NCT03363035
H-REPLACE-201711
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Shenghua Zhou, Second Xiangya Hospital of Central South University
Second Xiangya Hospital of Central South University
Not Provided
Principal Investigator: Shenghua Zhou, Ph.D. Second Xiangya Hospital of Central South University
Second Xiangya Hospital of Central South University
December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP